A multicenter open-label randomized study of BCD-020 (rituximab, CJSC BIOCAD, Russia) efficacy and safety in comparison with MabThera (F. Hoffmann-La Roche Ltd., Switzerland) in monotherapy of CD20-positive indolent non-Hodgkin's lymphoma

Trial Profile

A multicenter open-label randomized study of BCD-020 (rituximab, CJSC BIOCAD, Russia) efficacy and safety in comparison with MabThera (F. Hoffmann-La Roche Ltd., Switzerland) in monotherapy of CD20-positive indolent non-Hodgkin's lymphoma

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Follicular lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms BIORIX
  • Sponsors Biocad
  • Most Recent Events

    • 02 Nov 2017 Status changed from recruiting to completed.
    • 01 Sep 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Oct 2016.
    • 12 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top